Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis

BACKGROUND AND PURPOSE: Liver fibrosis is a major cause of liver‐related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF‐β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunis...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Pharmacol
Asıl Yazarlar: Luangmonkong, Theerut, Suriguga, Su, Bigaeva, Emilia, Boersema, Miriam, Oosterhuis, Dorenda, de Jong, Koert P, Schuppan, Detlef, Mutsaers, Henricus A M, Olinga, Peter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Research Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573419/
https://ncbi.nlm.nih.gov/pubmed/28691737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13945
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller